drugset
Drugs / MDX2001
last change Jan 2026 re-read 3 minutes ago

MDX2001

Developed for
biliary tract cancer · breast cancer · cervical cancer · endometrial cancer · esophageal cancer · gastric cancer · gastroesophageal cancer · head and neck cancer
+7 more · hepatocellular carcinoma · kidney cancer · malignant pancreatic neoplasm · non-small cell lung carcinoma · prostate cancer · rectal cancer · thyroid cancer
Investigated by
ModeX Therapeutics, An OPKO Health Company

Trials 1

today NCT06239194 · Ph 1/2
2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06239194 Jun 2024 → Aug 2028 expected biliary tract cancer, breast cancer, cervical cancer, endometrial cancer +11 ModeX Therapeutics, An OPKO Health Company Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MDX2001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06239194 ↗
Action Deplete “MDX2001 was developed to find cancer cells by identifying proteins on their cell surface and activate the body’s immune system to kill these cancer cells.” PMID 41495607 ↗ Jan 2026
Route Intravenous “Patients with metastatic solid tumors will receive MDX2001 as intravenous (IV) infusion.” NCT06239194 ↗